FAKTOR-OPTIONSSCHEIN - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 06:35:00 2024-06-14 EDT | ||
| 37.71 EUR / 39.52 EUR | +30.94% |
|
| Current month | -46.30% | ||
| 1 month | +51.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 36.44 | +23.57% |
| 24-06-13 | 29.49 | +5.81% |
| 24-06-12 | 27.87 | -11.61% |
| 24-06-11 | 31.53 | -16.83% |
| 24-06-10 | 37.91 | -3.34% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 06:07 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SN7D2T |
| ISIN | DE000SN7D2T5 |
| Date issued | 2022-07-28 |
| Strike | 73.59 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.24 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 58 € |
|---|---|
| Lowest since issue | 1.46 € |
| Spread | 1.81 € |
| Spread % | 4.73% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
